- Home
- PTGX
as 12-20-2024 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 2.7B | IPO Year: | 2016 |
| Target Price: | $54.63 | AVG Volume (30 days): | 767.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.43 - $48.89 | Next Earning Date: | 11-07-2024 |
| Revenue: | $323,795,000 | Revenue Growth: | 125.73% |
| Revenue Growth (this year): | 441.08% | Revenue Growth (next year): | -74.67% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Nov 26 '24 | Sell | $44.98 | 31,529 | $1,414,402.40 | 46,444 | |
| Gupta Suneel | PTGX | Chief Development Officer | Nov 25 '24 | Sell | $45.77 | 122,628 | $5,635,429.98 | 256,174 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Nov 25 '24 | Sell | $46.61 | 100,000 | $4,680,749.20 | 408,455 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Nov 15 '24 | Sell | $40.98 | 1,906 | $78,107.88 | 46,444 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
ACCESSWIRE
3 days ago
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Argus Research
5 days ago
PTGX: Lowering target price to $43.00
Argus Research
12 days ago
PTGX: Raising target price to $44.00
ACCESSWIRE
13 days ago
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
MT Newswires
16 days ago
Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target
TipRanks
16 days ago
Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities
Argus Research
19 days ago
PTGX: Lowering target price to $43.00
Simply Wall St.
23 days ago
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.